VGN50

£175.00 1mg

Blocks MYC activation.

VGN50 is a peptide derived from the Kaposi’s sarcoma-associated herpes virus transactivator (K-Rta) sequence, based on the
binding interface of K-Rta and cellular coactivators. VGN50 interacts with components of coactivators including nuclear receptor coactivator 2 (NCOA2), p300, and SWItch/Sucrose Non-Fermentable (SWI/SNF), the subfamily of ATP-dependent chromatin remodelling complex proteins. VGN50 blocks recruitment of the SWI/SNF complex and results in downregulation of both MYC and MYC-target gene transcription. Expression of MYC is tightly regulated in normal cells but becomes dysregulated in many types of human cancer cells, and application of VGN50 can reduce cell proliferation and selectively kill cancer cell lines in both tissue culture and a xenograft tumour mouse model.

Please contact us for availability.

SKU: PP-320 Categories: ,

Additional information

Other Names

K-Rta Peptide 1, Virus de Gann wo Naosu ORF50, K-Rta peptide

Three Letter Sequence

H-(D)Arg-Lys-Lys-Arg-Arg-Orn-Arg-Arg-Arg-?Ala-Leu-Ser-Ser-Ile-Leu-Gln-Gly-Leu-Tyr-Gln-Leu-Asp-Thr-OH

Molecular Weight

2827.7

Molecular Formula

C121H218N46O32

Sequence

rKKRR-Orn-RRR-?Ala-LSSILQGLYQLDT

Solubility

Soluble in water

Appearance

Freeze dried solid

Storage

Store dry, frozen and in the dark

Purity

>95% by HPLC

Modifications

D arginine at position 1, ornithine at position 6 and beta alanine at position 10

Searchable Words

VGN50, VGN 50, PP-320, PP320, K-Rta Peptide 1, Virus de Gann wo Naosu ORF50, rKKRR-Orn-RRR-?Ala-LSSILQGLYQLDT